menu
    • menu
    [{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Pasteur \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Institut Pasteur \/ Undisclosed"},{"orgOrder":0,"company":"Spaarne Gasthuis","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Spaarne Gasthuis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaarne Gasthuis \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Spaarne Gasthuis \/ ZonMw"},{"orgOrder":0,"company":"Mercy Health","sponsor":"Northeast Ohio Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercy Health \/ Northeast Ohio Medical University","highestDevelopmentStatusID":"8","companyTruncated":"Mercy Health \/ Northeast Ohio Medical University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Gentamicin Sulfate

    Menu

    Gentamicin Sulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spaarne Gasthuis

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Spaarne Gasthuis

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis

                            Details : Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Appendicitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

                            Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of atopic dermatitis. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mercy Health

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Mercy Health

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Northeast Ohio Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting

                            Details : Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2023

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Northeast Ohio Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $10.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

                            Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface an...

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $10.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $10.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

                            Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 29, 2022

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $10.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients...

                            Details : BioLexa is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms for patients suffering with Atopic Dermatitis.

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 21, 2022

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Ato...

                            Details : Receiving clearance for Cohort 2 is the next critical milestone in the Phase 1b clinical trial in Australia. Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and looks forward to advancing the treatment through the ...

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 12, 2021

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Tr...

                            Details : BioLexa is patented, proprietary antimicrobial topical formulation against diseases mediated by Staphylococcal biofilms. BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping bacteria in more susceptible state to antimicro...

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2021

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Hoth Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underw...

                            Details : The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate...

                            Product Name : BioLexa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2021

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Institut Pasteur

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Institut Pasteur

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Conservative Treatment of Catheter - Related Injections With Gentamicine/EDTA

                            Details : Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Catheter-Related Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2021

                            Lead Product(s) : Gentamicin Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth